Publications

My Publications

Primary Author

• Islam, F., et al. (2024). Integrative genetic variation, DNA methylation, and gene expression analysis of escitalopram and aripiprazole treatment outcomes in depression: a CAN-BIND-1 study. Pharmacopsychiatry, 57(5), 232-244.
• Islam, F., et al. (2024). Influence of CYP2C19, CYP2D6, and ABCB1 Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A CAN-BIND-1 Study. Canadian Journal of Psychiatry, 69(3), 183-195.
• Islam, F., et al. (2022). Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study. Translational Psychiatry, 12(1), 366.
• Islam, F., et al. (2022). Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis. Pharmacogenomics Journal, 22(4), 230-240.
• Islam, F., et al. (2021). Pharmacogenetics-Guided Advances in Antipsychotic Treatment. Clinical Pharmacology & Therapeutics, 110(3), 582-588.
• Islam, F., et al. (2021). Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression. Advances in Experimental Medicine and Biology, 1305, 231-255.
• Islam, F., et al. (2021). Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine/N-desmethylclozapine on working memory in schizophrenia. Journal of Psychopharmacology, 35(1), 31-39.
• Islam, F., et al. (2017). Brain-Derived Neurotrophic Factor Expression in Individuals With Schizophrenia and Healthy Aging: Testing the Accelerated Aging Hypothesis of Schizophrenia. Current Psychiatry Reports, 19(7), 36.
• Islam, F., et al. (2017). Inhibition of Wnt signalling dose-dependently impairs the acquisition and expression of amphetamine-induced conditioned place preference. Behavioural Brain Research, 326, 217-225.

Co-Author

• Adams, E., Islam, F., et al. (2025). Effects of Palliative Esophageal External Beam Radiation Therapy in Patients with Stent for Esophageal Cancer: A Retrospective Cohort Study. J Gastrointest Cancer, 56(1), 102.
• Magarbeh, L., Islam, F., et al. (2025). Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report. Canadian Journal of Psychiatry. In press.
• Elsheikh, S., Islam, F., et al. (2024). Genome‐Wide Associations of Cognitive Domains and their Correlation with Polygenic Risk Scores for Antidepressant Response in Late‐Life Depression. Alzheimer's & Dementia, 20(Suppl. 8), e095772.
• Elsheikh, S., Islam, F., et al. (2024). Polygenic score analyses on antidepressant response in Late-life Depression, Results from the IRL-GRey Study. The Pharmacogenomics Journal, 24(6), 38.
• Magarbeh, L., Islam, F., et al. (2023). ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta-Analysis Including Results from the CAN-BIND-1 Study. Clinical Pharmacology & Therapeutics, 114(1), 88-117.
• Marshe, V.S., Islam, F., et al. (2021). Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. Translational Psychiatry, 11(1), 127.
• Marshe, V.S., Islam, F., et al. (2020). Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 100, 109867.
• Marshe, V.S., Islam, F., et al. (2020). Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions. American Journal of Geriatric Psychiatry, 28(6), 609-629.

See full list and abstracts on Google Scholar.